PHARMACEUTICAL 2025

Jazz Pharmaceuticals plc
Rank 4 of 225



TOP RATED 2025

RealRate

PHARMACEUTICAL 2025

Jazz Pharmaceuticals plc
Rank 4 of 225

Jazz Pharmaceuticals

The relative strengths and weaknesses of Jazz Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Jazz Pharmaceuticals plc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 162% points.The greatest weakness of Jazz Pharmaceuticals plc is the variable Other Expenses, reducing the Economic Capital Ratio by 5.0% points.

The company's Economic Capital Ratio, given in the ranking table, is 420%, being 206% points above the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	4,629,028
Cost of Goods Sold	0
Intangible Assets	6,472,018
Liabilities, Current	1,038,573
Liabilities, Non-Current	0
Other Assets	911,211
Other Compr. Net Income	-105,520
Other Expenses	981,597
Other Liabilities	0
Other Net Income	-247,939
Other Revenues	4,068,950
Property and Equipment	0
Research and Development	894,000
Selling, General and Administrative Expense	1,385,294

Output Variable	Value in 1000 USD
Assets	12,012,257
Liabilities	1,038,573
Expenses	3,260,891
Revenues	4,068,950
Stockholders Equity	10,973,684
Net Income	560,120
Comprehensive Net Income	507,360
BaseVar	10,367,065
ECR before LimitedLiability	374%
Economic Capital Ratio	420%